A recent Wall Street Journal (WSJ) article outlines the unusual and extraordinary steps one of CICP's board member companies Eli Lilly and Co. had to take to develop a new antibody-based drug for COVID-19 that has now been approved by the U.S. Food and Drug Administration (FDA) for emergency use. The article states "What Lilly has gone through to get to this point reflects not only the common challenges all businesses face in the pandemic, but also unique ones that push drugmakers to the limit of their ability to operate." The WSJ article has been republished and can be found HERE.
Statement from Indiana Business Leaders: Governor Holcomb Meeting COVID-19 Challenges Compassionate, Data-Driven Approach Is Critical to Personal and Economic Health of Hoosiers (INDIANAPOLIS, April 28, 2020) – A group of business leaders from across Indiana today released the following joint statement in support of Governor Eric Holcomb and his team’s approach to ensuring the personal and economic health of Hoosiers during the COVID-19 pandemic. A list of participants follows. “We, the community of leaders from businesses and business associations across the state of Indiana, stand united as Indiana battles the twin threats posed by the pandemic emergency. The health of our fellow Hoosiers, and the health of Indiana’s economy, stand as inseparable challenges we must face together. These twin challenges are linked, as returning Indiana’s economy to normalcy ultimately requires vanquishing the COVID-19 threat. We recognize that our individual interests, [...]
INDIANAPOLIS (March 16, 2020) - Central Indiana Corporate Partnership (CICP) does not have any confirmed cases of COVID-19, but in an abundance of caution we have decided to take additional measures to ensure our risk remains low and to respond to community calls for social distancing that can help block additional spread of the virus. CICP has closed its offices but is continuing operations, as employees work from home. When making these difficult decisions, we continue to take into consideration guidelines from the Indiana State Department of Health and the Centers for Disease Control, along with recommendations from the City of Indianapolis, the State of Indiana, and our stakeholders. As always, the health and safety of our employees and their families are our top priorities. CICP and our initiatives AgriNovus Indiana, Ascend Indiana, BioCrossroads, Conexus Indiana, Energy Systems Network, and [...]